Clinical Insights on Treating Locally Advanced Breast Cancer

Opinion
Video

The Oncology Brothers and Virginia Kaklamani, MD, outline the treatment algorithm for patients with locally advanced HR+ breast cancer.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content
Four of 13 patients with metastatic breast cancer recruited in 2022 for the phase 2 clinical study evaluating Bria-IMT remain in survival follow-up.

Bria-IMT Regimen Exceeds Survival Data of SOC in Metastatic Breast Cancer

Roman Fabbricatore
October 23rd 2024
Article

Four of 13 patients with metastatic breast cancer recruited in 2022 for the phase 2 clinical study evaluating Bria-IMT remain in survival follow-up.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Bin Gui, MD, discussed how ultra-hypofractionated radiotherapy may be a convenient treatment option for elderly patients with early breast cancer.

Ultra-Hypofractionated RT Shows Control, Tolerability in Elderly Breast Cancer

Russ Conroy
October 17th 2024
Article

Bin Gui, MD, discussed how ultra-hypofractionated radiotherapy may be a convenient treatment option for elderly patients with early breast cancer.

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Finding a Place for Exercise Oncology in the Treatment of Breast Cancer

Neil M. Iyengar, MD
May 20th 2024
Podcast

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Phase 2 data indicate that the use of DetermaIO was predictive of a pathologic complete response with the addition of immunotherapy to chemotherapy in TNBC.

Gene Expression Test May Predict Added Atezolizumab Benefit in TNBC

Russ Conroy
October 9th 2024
Article

Phase 2 data indicate that the use of DetermaIO was predictive of a pathologic complete response with the addition of immunotherapy to chemotherapy in TNBC.

Investigators report no grade 4 adverse effects among patients who received elacestrant/abemaciclib in the phase 1b/2 ELECTRA trial.

Elacestrant Combo Shows Activity, Tolerability in Metastatic Breast Cancer

Jax DiEugenio
October 6th 2024
Article

Investigators report no grade 4 adverse effects among patients who received elacestrant/abemaciclib in the phase 1b/2 ELECTRA trial.